{
    "clinical_study": {
        "@rank": "45269", 
        "acronym": "Test-No Test", 
        "arm_group": [
            {
                "arm_group_label": "Empiric Dose Intensification", 
                "arm_group_type": "Active Comparator", 
                "description": "Intensify treatment with the existing drug"
            }, 
            {
                "arm_group_label": "Testing based strategy", 
                "arm_group_type": "Active Comparator", 
                "description": "Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the utilization of health resources in a testing\n      based strategy versus an empiric dose escalation strategy to manage Crohn's disease and\n      Ulcerative Colitis in subjects with loss of response to infliximab or adalimumab."
        }, 
        "brief_title": "Evaluation of Health Costs and Resource Utilization", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ulcerative Colitis", 
            "Crohn's Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males 18 years of age or older who are not receiving azathioprine or 6\n             mercaptopurine.\n\n          -  Non-pregnant, non-lactating females, 18 years of age or older.\n\n          -  Females of child bearing potential must have a negative serum pregnancy test prior to\n             randomization, and must use a hormonal (oral, implantable or injectable) or barrier\n             method of birth control throughout the study. [defined as a minimum of one year since\n             the last menstrual period]).\n\n          -  Documented diagnosis of CD or UC.\n\n          -  Active disease symptoms at visit 1 defined by: a. CD subjects: HBS ~ 6 UC subjects:\n             PMCS ~ 4.\n\n          -  Current infliximab therapy (naive to adalimumab) or current adalimumab therapy (naive\n             to infliximab ).\n\n          -  A minimum of 13 weeks of infliximab or adalimumab treatment prior to visit 1 at the\n             following dose:\n\n          -  Stable dose of azathioprine, 6 mercaptopurine, methotrexate, and/or\n             5-aminosalicylates in the 4 weeks prior to visit 1.\n\n        Exclusion Criteria:\n\n          -  Contraindication to the use of either infliximab or adalimumab.\n\n          -  Current infliximab treatment but not naive to adalimumab or\n\n          -  Current adalimumab treatment but not naive to infliximab.\n\n          -  Infliximab dosing prior to visit 1 was not 5 mg/kg at weeks 0, 2 and 6 and then q8w.\n\n          -  Adalimumab dosing prior to visit 1 was not 160 mg at week 0, 80 mg at week 2, and\n             then 40 mg q2w.\n\n          -  Received any investigational drug within 30 days prior to visit 1.\n\n          -  Serious underlying disease other than CD or UC which in the opinion of the\n             investigator may interfere with the subject's ability to participate fully in the\n             study.\n\n          -  History of alcohol or drug abuse which in the opinion of the investigator may\n             interfere with the subject's ability to comply with the study procedures.\n\n          -  Stools positive for clostridium difficile.\n\n          -  Pregnant or lactating women.\n\n          -  Change in dose of azathioprine, 6 mercaptopurine, methotrexate, and/or\n             5-aminosalicylates in the 4 weeks prior to visit 1.\n\n          -  Males 22 years of age or less who are receiving azathioprine or 6 mercaptopurine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960426", 
            "org_study_id": "RP1208"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testing based strategy", 
                "description": "Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.", 
                "intervention_name": "Measurement of drug (Adalimumab/Infliximab)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Empiric Dose Intensification", 
                "description": "Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist", 
                "intervention_name": "Intensify treatment with the existing drug", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Infliximab", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Harvey Bradshaw score", 
            "Partial Mayo Clinical Score", 
            "Infliximab", 
            "Adalimumab"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "email": "samantha@rockymtncr.com", 
                "last_name": "Paul Deneault, MD", 
                "phone": "303-279-1550"
            }, 
            "contact_backup": {
                "email": "samantha@rockymtncr.com", 
                "last_name": "Samantha Garrett", 
                "phone": "(303) 279-1550"
            }, 
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80222"
                }, 
                "name": "Rocky Mountain Gastroenterology Associates"
            }, 
            "investigator": {
                "last_name": "Paul Deneault, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease.", 
        "overall_contact": {
            "email": "joanne.depace@robartsinc.com", 
            "last_name": "Joanne Depace, BSc", 
            "phone": "(519) 931-5700", 
            "phone_ext": "24327"
        }, 
        "overall_official": {
            "affiliation": "Robarts Clinical Trials Inc. - Western University", 
            "last_name": "Brian Feagan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analysis of costs and outcomes will be made on an intention-to-treat basis", 
            "measure": "the mean difference in cumulative costs (Visit I to Week 3 1) between the two treatment arms", 
            "safety_issue": "No", 
            "time_frame": "31 weeks"
        }, 
        "reference": [
            {
                "PMID": "23357488", 
                "citation": "Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun;11(6):654-66. doi: 10.1016/j.cgh.2012.12.035. Epub 2013 Jan 26."
            }, 
            {
                "PMID": "15817555", 
                "citation": "Altman DG, Bland JM. Treatment allocation by minimisation. BMJ. 2005 Apr 9;330(7495):843. Review."
            }, 
            {
                "PMID": "16472588", 
                "citation": "Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2):323-33; quiz 591."
            }, 
            {
                "PMID": "17634458", 
                "citation": "Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19;357(3):228-38."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960426"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The proportion of subjects achieving clinical remission", 
            "measure": "The efficacy of the testing-based strategy compared to empiric dose intensification", 
            "safety_issue": "No", 
            "time_frame": "31 weeks"
        }, 
        "source": "University of Western Ontario, Canada", 
        "sponsors": {
            "collaborator": {
                "agency": "Prometheus Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Western Ontario, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}